Pelvital Stress Urinary Incontinence Training Device: P-SUIT
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Maple Grove, Minnesota, United States, 55369
- University of Minnesota Medical Center
-
Maplewood, Minnesota, United States, 55109
- Metro OBGYN
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Medical Center
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female gender,
- Ages 18-75,
- Clinical diagnosis of stress urinary incontinence,
- Ability to contract the pelvic floor muscles,
- Able to document incontinence and voiding in a diary,
- Provision of written informed consent form,
- Minimum of 10 grams increase at initial 24-hour pad weight test
Exclusion Criteria:
- Diagnosed mixed or urge urinary incontinence,
- Impaired cognitive function or neurologic conditions
- Physical limitations that impede the patient's ability to participate (e.g., ability to stand),
- Acute infections or hematuria,
- Pregnant or actively trying to conceive,
- History of pelvic irradiation,
- Concurrent medications with α-adrenergic antagonists or diuretics
- Pelvic organ prolapse stage III or IV,
- Severe urethral sphincter weakness and/or defect,
- Suspected urethral and/or vesical fistula
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pelvital probe
Probe to use for incontinence-Pevital is company name of product
|
Pelvital probe
|
|
Placebo Comparator: Placebo Probe
Placebo probe
|
Placebo Probe
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improvement in severity of involuntary urine loss
Time Frame: Baseline, 6 weeks
|
Measured by pad testing
|
Baseline, 6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
incontinence episode frequency
Time Frame: Baseline, 6 weeks
|
Daily Diary
|
Baseline, 6 weeks
|
|
health-related quality of life
Time Frame: Baseline, 6 weeks
|
Quality of Life questionarie
|
Baseline, 6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nissrine Nakib, MD, University of Minnesota
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- URO-2016-25004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.